Vanda Pharmaceuticals (VNDA) Reports In-Line Q2 EPS
Tweet
Share
E-mailGet Alerts VNDA Hot Sheet
Price: $5.11 +2.82%
Revenue Growth %: +59,101.9%
Financial Fact:
Total operating expenses: 39.14M
Today's EPS Names:
MAXN, CSTR, ACU, More
Revenue Growth %: +59,101.9%
Financial Fact:
Total operating expenses: 39.14M
Today's EPS Names:
MAXN, CSTR, ACU, More
Join SI Premium – FREE
Vanda Pharmaceuticals (NASDAQ: VNDA) reported Q2 EPS of ($0.05), in-line with the analyst estimate of ($0.05). Revenue for the quarter came in at $7.4 million versus the consensus estimate of $8.07 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Increasing unusual call option volume: MAXN VNDA TRV HIG IBKR LYV
- BancFirst Corp. (BANF) Tops Q1 EPS by 11c
- American Express (AXP) Tops Q1 EPS by 38c
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
